Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for molgramostim, an inhaled GM-CSF therapy, Savara’s story has shifted toward regulatory execution and commercial positioning, the firm says. Robust data from Phase 3 IMPALA-2 in autoimmune PAP support the BLA package and the firm’s view of a high-probability approval story, also given that prior FDA feedback was only CMC-related.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara says FDA extended review for Molgramostim BLA
- Savara: Regulatory Momentum and Strong Efficacy Data Support Buy Rating on MOLBREEVI in Autoimmune PAP
- Savara announces MHRA accepted submission of Molbreevi MAA
- Savara announces EMA validation of MAA for MOLBREEVI
- De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi